Clinically, the anti‐IL‐1β antibody Canakinumab has been approved by the FDA for the treatment of cryopyridine‐associated periodic syndrome (CAPS), tumor necrosis factor receptor‐associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS) and familial mediterranean fever (MFM) with good safety profiles. The gene discussed is IL1B; the disease is familial Mediterranean fever.